Medicus Pharma regains Nasdaq $1.00 bid price compliance days after delisting letter

Medicus Pharma Ltd. said Nasdaq has closed its minimum bid price case, three days after the exchange told the company it would delist its shares. In a Form 8-K dated October 20, 2026, the company reported that the Listing Qualifications Department of The Nasdaq Stock Market LLC sent written notice on October 23 that Medicus had regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Dr. Raza Bokhari, the Executive Chairman and Chief Executive Officer, signed the filing.

Ten business days above $1.00

Nasdaq found that the shares closed at $1.00 or more on each of the ten consecutive business days from October 12, 2026 to October 23, 2026. The common shares trade on The Nasdaq Capital Market as MDCX, and the warrants as MDCXW. Medicus is an Ontario company based in Conshohocken, Pennsylvania.

The timeline is the important part. Nasdaq first wrote to the company on April 21, 2026, after the shares had closed below $1.00 for 30 consecutive business days. Medicus then had until October 19, 2026 to fix the problem, and it did not. On October 20, Nasdaq staff sent a delisting determination letter covering the common shares and the warrants. Nasdaq said Medicus was not eligible for a second 180-day period because it did not meet the minimum $5 million stockholders' equity requirement for initial listing on the Nasdaq Capital Market.

The compliance notice superseded that letter. The 8-K does not say whether the company's stockholders' equity meets the $5 million standard today, although that was the reason Nasdaq gave for refusing more time. The company also declined to promise the result will last: "There can be no assurance that the Company will be able to maintain compliance with the Minimum Bid Price Requirement or Nasdaq's other continued listing requirements in the future."

Going-concern doubt and thin cash

The listing notice does not change the company's finances. Its annual report for 2025, filed March 25, 2026, says its auditor has expressed substantial doubt about its ability to continue as a going concern. The report also says the company is in the preliminary stages of its planned operations and has not yet determined whether its business plans are economically viable.

The company is developing SkinJect, a patch, and Teverelix, which is in open and planned Phase 2b studies. The annual report says the SkinJect Phase 1 study found the patch well tolerated, but there is no guarantee a Phase 2 study will produce similar results. It also warns that regulators may approve its products only with a less competitive label, and that the company relies on outside contract research organizations.

The company reported a net loss of $47.3 million for 2025, up from $11.2 million in 2024. Research and development expense rose to $7.7 million from $3.5 million. Cash used in operations was $22.8 million in 2025, against $10.2 million a year earlier. Cash and cash equivalents were $8.7 million at the end of 2025, compared with $4.2 million at the end of 2024, and $15.2 million at June 30, 2026, according to the company's quarterly report.

The annual report says the company's ability to commercialize its products depends on obtaining sufficient financing, and that investors could lose all or part of their investments if it cannot raise the money. The Nasdaq notice removes one immediate threat to the listing. It does not remove the need for money.

What the filing leaves open

The 8-K does not name a financing, a trial result or a board decision that would follow. It says only that the bid price matter is closed and that the company's continued listing still depends on Nasdaq's other rules. For a stock that spent 30 consecutive business days below $1.00 before the April notice, a ten-day recovery is a short record.

Report an error

Companies in this story

MDCXMedicus Pharma Ltd.NASDAQ · CanadaOpen the starter desk